Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Flu

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: Safety and immunogenicity of a combined Diphtheria, Tetanus, acellular Pertussis. Haemophilus influenzae type b, enhanced inactivated trivalent Poliovirus vaccine administered as a single injection to healthy Chilean Infants
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47157
    Study title: A proposition for the diagnosis and treatment of gastro-oesophageal reflux disease in children: a report from a working group on gastro-oesophageal reflux disease - Vandenplas Y - 1993 ( Eur. J. Pediatr. 1993; 152: 704-711) - Publication in Part IC3 - Expert report - Dupont C. - 03/02/1997A proposition for the diagnosis and treatment of gastro-oesophageal reflux disease in children: a report from a working group on gastro-oesophageal reflux disease - Vandenplas Y - 1993 ( Eur. J. Pediatr. 1993; 152: 704-711) - Publication in Part IC3 - Expert report - Dupont C. - 03/02/1997
    Active substance: ALGELDRATE + MAGNESIUM HYDROXIDE + SIMETICONE/ ALDEGRATE+ MAGNESIUM HYDROXIDE
    Study summary document link (including results):
    View full study record
    Document reference: 46383
    Study title: A proposition for the diagnosis and treatment of gastro-oesophageal reflux disease in children: a report from a working group on gastro-oesophageal reflux disease - Vandenplas Y - 1993 ( Eur. J. Pediatr. 1993; 152: 704-711) - Publication in Part IC3 - Expert report - Dupont C. - 03/02/1997A proposition for the diagnosis and treatment of gastro-oesophageal reflux disease in children: a report from a working group on gastro-oesophageal reflux disease - Vandenplas Y - 1993 ( Eur. J. Pediatr. 1993; 152: 704-711) - Publication in Part IC3 - Expert report - Dupont C. - 03/02/1997
    Active substance: ALGELDRATE + MAGNESIUM HYDROXIDE + SIMETICONE/ ALDEGRATE+ MAGNESIUM HYDROXIDE
    Study summary document link (including results):
    View full study record
    Document reference: 46396
    Study title: A proposition for the diagnosis and treatment of gastro-oesophageal reflux disease in children: a report from a working group on gastro-oesophageal reflux disease - Vandenplas Y - 1993 ( Eur. J. Pediatr. 1993; 152: 704-711) - Publication in Part IC3 - Expert report - Dupont C. - 03/02/1997A proposition for the diagnosis and treatment of gastro-oesophageal reflux disease in children: a report from a working group on gastro-oesophageal reflux disease - Vandenplas Y - 1993 ( Eur. J. Pediatr. 1993; 152: 704-711) - Publication in Part IC3 - Expert report - Dupont C. - 03/02/1997
    Active substance: ALGELDRATE + MAGNESIUM HYDROXIDE + SIMETICONE/ ALDEGRATE+ MAGNESIUM HYDROXIDE
    Study summary document link (including results):
    View full study record
    Document reference: 46411
    Study title: A proposition for the diagnosis and treatment of gastro-oesophageal reflux disease in children: a report from a working group on gastro-oesophageal reflux disease - Vandenplas Y - 1993 ( Eur. J. Pediatr. 1993; 152: 704-711) - Publication in Part IC3 - Expert report - Dupont C. - 03/02/1997A proposition for the diagnosis and treatment of gastro-oesophageal reflux disease in children: a report from a working group on gastro-oesophageal reflux disease - Vandenplas Y - 1993 ( Eur. J. Pediatr. 1993; 152: 704-711) - Publication in Part IC3 - Expert report - Dupont C. - 03/02/1997
    Active substance: ALGELDRATE + MAGNESIUM HYDROXIDE + SIMETICONE/ ALDEGRATE+ MAGNESIUM HYDROXIDE
    Study summary document link (including results):
    View full study record
    Document reference: 46421
    Study title: Antiacids and cimetidine treatment for-gastro-oesophageal reflux and peptic oesophagitis - Cucchiara S - 1984 ( Arch. Dis. Child. 1984; 59: 842-847) - Publication in Part IC3 - Expert Report - Dupont C - 03/02/1997 -Antiacids and cimetidine treatment for-gastro-oesophageal reflux and peptic oesophagitis - Cucchiara S - 1984 ( Arch. Dis. Child. 1984; 59: 842-847) - Publication in Part IC3 - Expert Report - Dupont C - 03/02/1997 -
    Active substance: ALGELDRATE + MAGNESIUM HYDROXIDE + SIMETICONE/ ALDEGRATE+ MAGNESIUM HYDROXIDE
    Study summary document link (including results):
    View full study record
    Document reference: 46384
    Study title: Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. A double-blind randomized study versus placebo - Carroccio A - 1994 (Scand. J. Gastroenterol 1994; 29 (4): 300-304) - Publication in Part 1C3 expert report - Dupont C. - 03/02/1997 -Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. A double-blind randomized study versus placebo - Carroccio A - 1994 (Scand. J. Gastroenterol 1994; 29 (4): 300-304) - Publication in Part 1C3 expert report - Dupont C. - 03/02/1997 -
    Active substance: ALGELDRATE + MAGNESIUM HYDROXIDE + SIMETICONE/ ALDEGRATE+ MAGNESIUM HYDROXIDE
    Study summary document link (including results):
    View full study record
    Document reference: 46386
    Study title: Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. A double-blind randomized study versus placebo - Carroccio A - 1994 (Scand. J. Gastroenterol 1994; 29 (4): 300-304) - Publication in Part 1C3 expert report - Dupont C. - 03/02/1997 -Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. A double-blind randomized study versus placebo - Carroccio A - 1994 (Scand. J. Gastroenterol 1994; 29 (4): 300-304) - Publication in Part 1C3 expert report - Dupont C. - 03/02/1997 -
    Active substance: ALGELDRATE + MAGNESIUM HYDROXIDE + SIMETICONE/ ALDEGRATE+ MAGNESIUM HYDROXIDE
    Study summary document link (including results):
    View full study record
    Document reference: 46397
    Study title: Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. A double-blind randomized study versus placebo - Carroccio A - 1994 (Scand. J. Gastroenterol 1994; 29 (4): 300-304) - Publication in Part 1C3 expert report - Dupont C. - 03/02/1997 -Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. A double-blind randomized study versus placebo - Carroccio A - 1994 (Scand. J. Gastroenterol 1994; 29 (4): 300-304) - Publication in Part 1C3 expert report - Dupont C. - 03/02/1997 -
    Active substance: ALGELDRATE + MAGNESIUM HYDROXIDE + SIMETICONE/ ALDEGRATE+ MAGNESIUM HYDROXIDE
    Study summary document link (including results):
    View full study record
    Document reference: 46400
    Study title: Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. A double-blind randomized study versus placebo - Carroccio A - 1994 (Scand. J. Gastroenterol 1994; 29 (4): 300-304) - Publication in Part 1C3 expert report - Dupont C. - 03/02/1997 -Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. A double-blind randomized study versus placebo - Carroccio A - 1994 (Scand. J. Gastroenterol 1994; 29 (4): 300-304) - Publication in Part 1C3 expert report - Dupont C. - 03/02/1997 -
    Active substance: ALGELDRATE + MAGNESIUM HYDROXIDE + SIMETICONE/ ALDEGRATE+ MAGNESIUM HYDROXIDE
    Study summary document link (including results):
    View full study record
    Document reference: 46414
    Study title: Large Scale Safety Study of the DTacP-IPV (Acellular ~etraco~@Va)c cine, Adrninistered in Combination (one injection site) or in Association (two injection sites) with Haemophilus influenzae type b Vaccine (Act-HIE"') for Primary and Booster immunisation.
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47156
    Study title: Double-blind controlled study on the efficacy of sodium-alginate (Gaviscon®) in reducing gastro-eosphageal reflux assessed by 24h continous pH monitoring in infants and children - Buts JP - 1987 (Eur. J. Pediatr. 1987; 145: 156-158) - Publication in Part 1C3 expert report - Dupont C. - 03/02/1997 -Double-blind controlled study on the efficacy of sodium-alginate (Gaviscon®) in reducing gastro-eosphageal reflux assessed by 24h continous pH monitoring in infants and children - Buts JP - 1987 (Eur. J. Pediatr. 1987; 145: 156-158) - Publication in Part 1C3 expert report - Dupont C. - 03/02/1997 -
    Active substance: ALGELDRATE + MAGNESIUM HYDROXIDE + SIMETICONE/ ALDEGRATE+ MAGNESIUM HYDROXIDE
    Study summary document link (including results):
    View full study record
    Document reference: 46424
    Study title: Manifestations respiratoires associées aux reflux gastro-oesophagien chez l'adulte et l'enfant - Denis P - 1984 (Gastroenterol Clin Biol 1984; 8:758-765) - Publication in Part IC3 of Maalox TC Suspension buvable comprimé (France Initial application dossier) - Galmiche JP - 1989Manifestations respiratoires associées aux reflux gastro-oesophagien chez l'adulte et l'enfant - Denis P - 1984 (Gastroenterol Clin Biol 1984; 8:758-765) - Publication in Part IC3 of Maalox TC Suspension buvable comprimé (France Initial application dossier) - Galmiche JP - 1989
    Active substance: ALGELDRATE + MAGNESIUM HYDROXIDE + SIMETICONE/ ALDEGRATE+ MAGNESIUM HYDROXIDE
    Study summary document link (including results):
    View full study record
    Document reference: 46390
    Study title: Manifestations respiratoires associées aux reflux gastro-oesophagien chez l'adulte et l'enfant - Denis P - 1984 (Gastroenterol Clin Biol 1984; 8:758-765) - Publication in Part IC3 of Maalox TC Suspension buvable comprimé (France Initial application dossier) - Galmiche JP - 1989Manifestations respiratoires associées aux reflux gastro-oesophagien chez l'adulte et l'enfant - Denis P - 1984 (Gastroenterol Clin Biol 1984; 8:758-765) - Publication in Part IC3 of Maalox TC Suspension buvable comprimé (France Initial application dossier) - Galmiche JP - 1989
    Active substance: ALGELDRATE + MAGNESIUM HYDROXIDE + SIMETICONE/ ALDEGRATE+ MAGNESIUM HYDROXIDE
    Study summary document link (including results):
    View full study record
    Document reference: 46402
    Study title: Manifestations respiratoires associées aux reflux gastro-oesophagien chez l'adulte et l'enfant - Denis P - 1984 (Gastroenterol Clin Biol 1984; 8:758-765) - Publication in Part IC3 of Maalox TC Suspension buvable comprimé (France Initial application dossier) - Galmiche JP - 1989Manifestations respiratoires associées aux reflux gastro-oesophagien chez l'adulte et l'enfant - Denis P - 1984 (Gastroenterol Clin Biol 1984; 8:758-765) - Publication in Part IC3 of Maalox TC Suspension buvable comprimé (France Initial application dossier) - Galmiche JP - 1989
    Active substance: ALGELDRATE + MAGNESIUM HYDROXIDE + SIMETICONE/ ALDEGRATE+ MAGNESIUM HYDROXIDE
    Study summary document link (including results):
    View full study record
    Document reference: 46418
    Study title: LMD77293 - Killian A, Davis PJ, Stiller RL, Cicco R, Cook DR, Guthrie RD. Influence of gestational age on pharmacokinetics of alfentanil in neonates. Developmental Pharmacology and Therapeutics, 15 (2), p. 82-85, 1990.LMD77293 - Killian A, Davis PJ, Stiller RL, Cicco R, Cook DR, Guthrie RD. Influence of gestational age on pharmacokinetics of alfentanil in neonates. Developmental Pharmacology and Therapeutics, 15 (2), p. 82-85, 1990.
    Active substance: ALFENTANIL
    Study summary document link (including results):
    View full study record
    Document reference: 46350
    Study title: A multicentric randomized clinical trial of Gaviscon in reflux esophagitis - McHardy G - 1978 (South Med. J. 1978; 71 (Suppl 1) 16-20) - Publication in Part IC3 - Expert Report - Dupont C - 03/02/1997 -A multicentric randomized clinical trial of Gaviscon in reflux esophagitis - McHardy G - 1978 (South Med. J. 1978; 71 (Suppl 1) 16-20) - Publication in Part IC3 - Expert Report - Dupont C - 03/02/1997 -
    Active substance: ALGELDRATE + MAGNESIUM HYDROXIDE + SIMETICONE/ ALDEGRATE+ MAGNESIUM HYDROXIDE
    Study summary document link (including results):
    View full study record
    Document reference: 46382
    Study title: Gupta SK, Gambhir S, Mithal A, Das BK. Skeletal scintigraphic findings in endemic skeletal fluorosis. Nucl Med Commun. 1993 May;14(5):384-90. Gupta SK, Gambhir S, Mithal A, Das BK. Skeletal scintigraphic findings in endemic skeletal fluorosis. Nucl Med Commun. 1993 May;14(5):384-90.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 43664
    Study title: Manifestations respiratoires associées aux reflux gastro-oesophagien chez l'adulte et l'enfant - Denis P - 1984 (Gastroenterol Clin Biol 1984; 8:758-765) - Publication in Part IC3 of Maalox TC Suspension buvable comprimé (France Initial application dossier) - Galmiche JP - 1989Manifestations respiratoires associées aux reflux gastro-oesophagien chez l'adulte et l'enfant - Denis P - 1984 (Gastroenterol Clin Biol 1984; 8:758-765) - Publication in Part IC3 of Maalox TC Suspension buvable comprimé (France Initial application dossier) - Galmiche JP - 1989
    Active substance: ALGELDRATE + MAGNESIUM HYDROXIDE + SIMETICONE/ ALDEGRATE+ MAGNESIUM HYDROXIDE
    Study summary document link (including results):
    View full study record
    Document reference: 46425
    Study title: Reflux esophagitis in infants and children: a report from the working group on gastro-oesophageal reflux disease of European Society of Paediatric Gastroenterology and Nutrition - Vandenplas Y - 1994 (J. Pediatr. Gastroenterol. Nutri. 1994; 18: 413-422) - Publication in Part IC3 - Expert Report - Dupont C - 03/02/1997 -Reflux esophagitis in infants and children: a report from the working group on gastro-oesophageal reflux disease of European Society of Paediatric Gastroenterology and Nutrition - Vandenplas Y - 1994 (J. Pediatr. Gastroenterol. Nutri. 1994; 18: 413-422) - Publication in Part IC3 - Expert Report - Dupont C - 03/02/1997 -
    Active substance: ALGELDRATE + MAGNESIUM HYDROXIDE + SIMETICONE/ ALDEGRATE+ MAGNESIUM HYDROXIDE
    Study summary document link (including results):
    View full study record
    Document reference: 46399
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Feb 14 02:22:53 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA